Drugs / PF-00232798
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01140425 | Jul → Dec 2010 | — | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00495677 Comparator | Jun 2007 → Sep 2008 | HIV infectious disease | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-00232798 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00495677 ↗ |
| Action | Inhibit | “C-C chemokine receptor type 5 inhibitor” CHEMBL1649931 ↗ |
| Modality | Small molecule | — CHEMBL1649931 ↗ |
| Route | Oral | “multiple oral doses of PF 00232798” NCT00495677 ↗ |
| Target | CCR5 | “C-C chemokine receptor type 5 inhibitor” CHEMBL1649931 ↗ |